Axial Therapeutics Inc. news
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will participate in a panel titled “Placing Patients At The Center” at the Longwood Healthcare Leaders Spring MIT webconference on Wednesday, May 4, 2022. The event is being held virtually May 4-5, 2022.
Longwood Health
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions, today announced that its scientific founder and California Institute of Technology (Caltech) Professor, Sarkis Mazmanian, Ph.D., will be presenting at TACA’s Autism Action Conference, taking place virtually from April 8-9, 2022. The presentation titled, “Gut-Brain Axis: How substances produced by the microbiome may contribute to Auti
- Open-label study showed Axial’s Lead Candidate, AB-2004, is safe and well-tolerated in an adolescent ASD cohort
- AB-2004 lowered blood and urinary levels of gut-derived metabolites and significantly improved irritability and anxiety
- Research supports company’s clinical development strategy focused on gut-targeted therapeutics for managing irritability associated with autism
Axial Therapeutics, a clinical-stage bi
- Study adds to growing evidence for how gut microbiome impacts Central Nervous System (CNS) function and behavior in mice
- Research offers valuable mechanistic insights for understanding the potential role of microbial metabolites in neurodevelopmental disorders
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions, today announced the publication of preclinical resear
- Advancement of first program from Axial platform into a randomized Phase 2b clinical trial signifies key milestone for company
- Trial is enrolling approximately 195 autistic adolescents at clinical trial sites in the United States, Australia and New Zealand
- Phase 2 trial is based on positive results from open-label Phase 1b/2a trial that demonstrated a favorable safety profile for AB-2004 as well as improvement in irritability scores
Axial Therapeutic
- Global, placebo-controlled Phase 2b trial now enrolling in the U.S., Australia and New Zealand
- Axial is activating 20 Phase 2b clinical trial sites in the U.S. and seven clinical sites in Australia and New Zealand
- Clinical studies to date confirm AB-2004’s strong safety profile and potential to address large unmet treatment need in irritability associated with autism spectrum disorder (ASD)
Axial Therapeutics, a clini
- Proceeds will support Axial`s randomized, controlled Phase 2b clinical trial for lead candidate, AB-2004, a molecular therapeutic to treat irritability in children with autism
- Funding positions company for platform and pipeline growth
- Completion of new round brings total investment in company to $91.5 million to date
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, t
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021. The summit is a virtual event and the presentation wil
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging the gut-brain axis for the discovery and development of small molecule therapeutics with an initial focus on autism spectrum disorder (ASD) and Parkinson’s disease (PD), today announced the appointment of A. Stewart Campbell, Ph.D. as Chief Executive Officer (CEO). Dr. Campbell will also serve as a member on the Axial Board of Directors.
“Stew is a proven executive leader with extensi
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference 2021. The session will become available for on-demand viewing at 6:00 a.m. ET on Monday, Jan. 11, 2021.
About Axial Therapeutics
Axial Therapeutic